Your session is about to expire
← Back to Search
[18F]APN-1607 PET Scan for Progressive Supranuclear Palsy
Study Summary
This trial is testing a new PET scan to measure tau pathology in people with Progressive Supranuclear Palsy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
What are the eligibility criteria for participating in this experimental protocol?
"This medical trial seeks 18 individuals between the ages of 50 and 80 with a diagnosis of progressive supranuclear palsy (PSP)."
How could [18F] APN-1607 potentially impact human health?
"As this is only a Phase 1 trial, there are limited safety and efficacy data available. Therefore, our team at Power has assigned [18F] APN-1607 a score of 1 on the risk scale."
How many individuals are being included in this experiment?
"Affirmative. Clinicaltrials.gov data provides evidence that this experiment is actively seeking participants; the trial was initially posted on May 25th 2021 and revised most recently on July 1st 2022, with 18 patients required across a single medical facility."
Does this clinical trial have an age limit, and if so, what is it?
"Participants to this trial must be between 50 and 80 years old. Separately, there are separate trials for those under 18 (50) and over 65 (390)."
Is there room to enroll participants in this experiment?
"Affirmative, clinicaltrials.gov displays that this research is still searching for participants since its initiation on May 25th 2021 and the latest update on July 1st 2022. The trial requires 18 test subjects found at one site specifically."
Share this study with friends
Copy Link
Messenger